Use of rituximab in diffuse large B-cell lymphoma in the salvage setting-Reference-Cited by-同舟云学术

Use of rituximab in diffuse large B-cell lymphoma in the salvage setting

Published:2008-12 Issue:5 Volume:143 Page:607-621
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Gisselbrecht Christian

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07383.x/fullpdf

Reference96 articles.

1. Rituximab-ESHAP as salvage therapy in relapsed aggressive B cell lymphoma;Arnold;Haematologica,2005

2. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients;Aydin;Annals of Hematology,2007

3. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin’s lymphoma patients: a prospective randomized GEMOH report;Baldissera;Acta Haematologica,2006

4. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL);Betticher;Annals of Oncology,2006

5. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma;Bieker;Oncology Reports,2003

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Large B-Cell Lymphoma of the Cecum;ACG Case Reports Journal;2023-02

2. A rare case of diffuse large B-cell lymphoma presenting as a malignant mass in both duodenum and ascending colon;Radiology Case Reports;2022-09

3. Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study);Hematological Oncology;2022-06-05

4. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy;European Journal of Haematology;2021-02-04

Long Noncoding RNA SNHG12 Indicates the Prognosis and Accelerates Tumorigenesis of Diffuse Large B-Cell Lymphoma Through Sponging microR-195

;OncoTargets and Therapy;2020-06